Sneddon syndrome: a comprehensive clinical review of 53 patients

被引:17
作者
Starmans, N. L. P. [1 ]
van Dijk, M. R. [2 ]
Kappelle, L. J. [1 ]
Frijns, C. J. M. [1 ]
机构
[1] Univ Med Ctr, Dept Neurol & Neurosurg, Room G03-232,POB 85500, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands
关键词
Livedo reticularis; Stroke; Sneddon syndrome; Antiphospholipid antibodies; Risk factors; TRANSIENT ISCHEMIC ATTACK; HEMORRHAGE; STATEMENT; DISEASE;
D O I
10.1007/s00415-021-10407-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The presence of livedo reticularis in patients with ischaemic stroke is associated with Sneddon syndrome (SS). Our objective was to present the clinical features of SS patients and to assess the role of antiphospholipid antibodies (APL). Methods Consecutive patients, diagnosed with SS between 1996 and 2017, were retrospectively reviewed for their demographic, neurological, dermatological, cardiac and extracerebral vascular features. Diagnosis of SS was made only if other causes of stroke were excluded. Patients with and without APL were included and compared for their clinical features. Results Fifty-three patients (79% female) were included, of whom 14 patients were APL-positive. Median age at diagnosis was 40 years. Approximately 60% of the patients had >= 3 cardiovascular risk factors. There were 129 previous vascular events (66 ischaemic strokes, 62 TIAs and 1 amaurosis fugax) during a median period of 2 years between the first event and diagnosis of SS. Skin biopsy was positive for SS in 29 patients (67%), mostly showing a thickened vessel wall with neovascularization in the deep dermis. After a median follow-up of 28 months, 4 patients, either on antiplatelet or oral anticoagulation therapy, had a recurrent stroke. There were few statistically significant differences between APL-negative and APL-positive patients, including the number of vascular events before diagnosis. Conclusions SS predominantly affects young women with a relatively large number of cardiovascular risk factors. Clinical features of SS are comparable across different studies. We found no differences in the main clinical features between APL-positive and APL-negative patients.
引用
收藏
页码:2450 / 2457
页数:8
相关论文
共 20 条
[1]   Intraventricular Hemorrhage as an Unusual Presenting Form of Sneddon Syndrome [J].
Bayrakli, Fatih ;
Erkek, Emel ;
Kurtuncu, Murat ;
Ozgen, Serdar .
WORLD NEUROSURGERY, 2010, 73 (04) :411-413
[2]   The natural course of Sneddon syndrome:: clinical and magnetic resonance imaging findings in a prospective six year observation study [J].
Boesch, SM ;
Plörer, AL ;
Auer, AJ ;
Poewe, W ;
Aichner, FT ;
Felber, SR ;
Sepp, NT .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (04) :542-544
[3]  
Bolayir E, 2004, ACTA MED OKAYAMA, V58, P59
[4]   Strokes in Sneddon Syndrome without Antiphospholipid Antibodies [J].
Bottin, Laure ;
Frances, Camille ;
de Zuttere, Dominique ;
Boelle, Pierre-Yves ;
Muresan, Ioan-Paul ;
Alamowitch, Sonia .
ANNALS OF NEUROLOGY, 2015, 77 (05) :817-829
[5]   Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH [J].
Devreese, K. M. J. ;
Ortel, T. L. ;
Pengo, V. ;
de Laat, B. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (04) :809-813
[6]   Definition and Evaluation of Transient Ischemic Attack A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. [J].
Easton, J. Donald ;
Saver, Jeffrey L. ;
Albers, Gregory W. ;
Alberts, Mark J. ;
Chaturvedi, Seemant ;
Feldmann, Edward ;
Hatsukami, Thomas S. ;
Higashida, Randall T. ;
Johnston, S. Claiborne ;
Kidwell, Chelsea S. ;
Lutsep, Helmi L. ;
Miller, Elaine ;
Sacco, Ralph L. .
STROKE, 2009, 40 (06) :2276-2293
[7]   THE UNITED-KINGDOM TRANSIENT ISCHEMIC ATTACK (UK-TIA) ASPIRIN TRIAL - FINAL RESULTS [J].
FARRELL, B ;
GODWIN, J ;
RICHARDS, S ;
WARLOW, C .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1991, 54 (12) :1044-1054
[8]  
FAZEKAS F, 1987, AM J NEURORADIOL, V8, P421
[9]   Clinical and neuroradiological aspects of Sneddon's syndrome and primary antiphospholipid antibody syndrome. A follow-up study [J].
Fetoni, V ;
Grisoli, N ;
Salmaggi, A ;
Carriero, R ;
Girotti, F .
NEUROLOGICAL SCIENCES, 2000, 21 (03) :157-164
[10]   Therapy of Sneddon syndrome [J].
Flöel, A ;
Imai, T ;
Lohmann, H ;
Bethke, F ;
Sunderkötter, C ;
Droste, DW .
EUROPEAN NEUROLOGY, 2002, 48 (03) :126-132